Major Milestone Reached: COVend’s IXION 2.0 trial enrols its first patients!

We are excited to announce the start of patient enrollment for the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Due to the evolving dynamics of COVID-19, the project’s focus has shifted to investigating the potential benefits of the FX06 drug for patients with acute respiratory distress syndrome (ARDS). Spearheaded by Prof. Zacharowski and Dr. Petra Wülfroth, the co-founder of F4 Pharma in Vienna, the consortium and clinical trial were restructured in record time, underlining the unwavering joint commitment to innovative medical research in critical health conditions.

Read More »

Groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome: FX06 is Pioneering New Frontiers in Clarkson Disease Treatment

Our COVend consortium member F4 Pharma’s cooperation partners presented groundbreaking research on Idiopathic Systemic Capillary Leak Syndrome (ISCLS), also known as Clarkson disease, first at the 124° Congresso Nazionale of the Societa Italiana di Medicina Interna (SIMI) in October 2023. Now their paper is officially published in Biomedicine & Pharmacotherapy.

Read More »

COVend presented at ISPOR Europe 2023

On the 13th of November, the consortium member of our partner institution UMCG, Clazinus Veijer, presented his poster “Lessons learned from model-based economic evaluations of COVID-19 treatments under pandemic circumstances: results from a systematic review ” at ISPOR Europe 2023. The poster highlighted results from a systematic review of various methodological characteristics of model-based economic evaluations of COVID-19 treatments.

Read More »
image depicting two SDG icons

COVend and UN SDGs: Contributing to Shaping a Healthier World

In 2015, the United Nations adopted the 17 Sustainable Development Goals (SDGs) as a global blueprint for addressing pressing challenges. These goals guide our efforts to combat poverty, inequality, climate change, and environmental concerns. Among them, two pivotal goals stand out – SDG 3: Good Health and Well-being, and SDG 9: Industry, Innovation and Infrastructure.

Read More »
image depicting a loudspeaker and the announcement "Big news for the COVend project"

New Findings on FX06 and its Therapeutic Potential from the COVend Research Teams

What do an economist, a biochemist, and a clinician have in common? As it turns out, they can all benefit from the latest findings on FX06. The researchers from University College Dublin and the University Medical Center Groningen, the esteemed COVend consortium partners, have revealed new information on FX06 and its potential role in addressing hyperinflammation and capillary leak.

Read More »

The study protocol of IXION

We are happy to announce that after just about a year from the project start, the study protocol of IXION has now been published! Background More than 2.7 million hospitalizations

Read More »

COVend represented in Euroanaesthesia 2022

COVend represented in Euroanaesthesia 2022 Euroanaesthesia is recognised worldwide as one of the most important and influential annual congresses in anaesthesiology and intensive care. During this year’s edition, COVend was

Read More »
COVend Partners

Celebrating Women and Girls in Science

Today we are celebrating Women and Girls in Science with our partner Petra Wülfroth, Ph.D. Dr. Wülfroth is a pharmacist and pharmacologist by training with more than 30 years of

Read More »
Clinical Study

Ethics Go Ahead for COVend

Submissions to Competent Authorities and Ethics Committees for IXION study Starting in December 2021, our COVend researchers submitted to both their Competent Authority and Ethics Committee in different countries to

Read More »

A portrait of Prof. Kai Zacharowski

Coordinator of the COVend project, Prof. Dr. Dr. Kai Zacharowski, MD PhD ML FRCA is the Director of the Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy at the

Read More »

Kicking off COVend!

On the 31st August all partners of COVend had a successful online meeting marking the official Kick-Off of this new Horizon 2020 project which will run until August 2024. All 17

Read More »